(Q37977498)

English

Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer

scientific article published on 21 January 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 August 2017

Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer (English)

1 reference

Europe PubMed Central

26 August 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maria Vittoria Dieci

object named as

Maria Vittoria Dieci

2

0 references

Valentina Guarneri

object named as

Valentina Guarneri

1

0 references

Pierfranco Conte

object named as

Pierfranco Conte

3

0 references

language of work or name

0 references

publication date

21 January 2012

1 reference

Europe PubMed Central

26 August 2017

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

26 August 2017

13

1 reference

Europe PubMed Central

26 August 2017

395-406

1 reference

Europe PubMed Central

26 August 2017

3

1 reference

Europe PubMed Central

26 August 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Pharmacological effects of formulation vehicles : implications for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Role of formulation vehicles in taxane pharmacology

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Albumin-bound paclitaxel: a next-generation taxane

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Weekly nab-paclitaxel is safe and effective in ≥65 years old patients with metastatic breast cancer: a post-hoc analysis.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Docetaxel-based combination therapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Novel markers for poor prognosis in head and neck cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Gp60 Activation Mediates Albumin Transcytosis in Endothelial Cells by Tyrosine Kinase-dependent Pathway

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.651127

21 January 2018

Identifiers

10.1517/14656566.2012.651127

1 reference

Europe PubMed Central

26 August 2017

1 reference

Europe PubMed Central

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37977498&oldid=1966912706"